By: Peter Olins, PhD on February 5, 2014.
BioLineRx is developing a new compound that might “sequester” gluten, preventing it from activating the immune system of celiacs. Their chemical compound, BL-7010, has just entered the first Phase 1/II clinical trials, where the focus will be safety. They also may some information about the drug’s efficacy. If BL-7010 proves to be safe, the BioLineRx hopes to launch a Phase II clinical trial later this year, to examine efficacy in more detail.
Press Release: BioLineRx Enters Clinic with Novel Treatment for Celiac Disease
Leave a Reply